Markets BTIG starts coverage of six cell therapy and immuno-oncology companies at buy BTIG initiated coverage on six companies with “buy” ratings that it believes are undervalued players in the cell therapy space, each developing some variation of autologous CAR-Ts, “off-the-shelf” allogeneic CAR-Ts... May 17, 2021